EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Childhood‐Onset Filamin c Related Cardiomyopathy: Genotype–Phenotype Correlation and Outcome

Evelien Cansse, Wannes Renders, Luc Bruyndonckx, Bert Callewaert, Katya De Groote, Ruth Heying, Jelena Hubrechts, Stéphane Moniotte, Thomas Salaets, Laura Muiño Mosquera

Clinical Genetics · 2026-12 · 110 (6) · 724-735

DOI: 10.1111/cge.70248 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT Filamin C ( FLNC ) contributes to 1%–8% of adult‐onset cardiomyopathy (CMP), with a high prevalence of end‐stage heart failure and sudden cardiac death, particularly for FLNC truncating variants ( FLNCtv ), rendering it one of the high‐risk CMP genes. Outcome data and genotype–phenotype correlation in children are scarce. We conducted a retrospective cohort study of children (< 18 years) with CMP features and a (likely) pathogenic FLNC variant, identified via literature search or in the Belgian Pediatric Cardiology Registry (BePCaR), to evaluate cardiovascular outcomes and genotype–phenotype correlations. Seventy‐four individuals (56.8% male, median age 4.5 years) from 57 families were included. Restrictive CMP was the most prevalent phenotype. Half of the patients experienced major adverse cardiovascular events, including heart transplantation (20.3%) and death (13.5%). Hypertrophic CMP was exclusively associated with ROD2 domain variants. Mortality was significantly higher in FLNCtv carriers versus non‐truncating carriers (26.9% vs. 6.3%, p = 0.019), and multivariate analysis identified FLNCtv as an independent predictor of adverse outcome (OR = 6.4, 95% CI: [1.36, 29.80]). Extracardiac manifestations occurred in 32.4%, predominantly in RCM patients, with myopathy‐associated variants clustering in exons 21 and 41. Pathogenic FLNC variants associate with early‐onset CMP and poor prognosis, underscoring the need for early genetic screening, risk stratification, and personalized follow‐up to improve outcome.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →